Opendata, web and dolomites

NovAnI SIGNED

Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovAnI project word cloud

Explore the words cloud of the NovAnI project. It provides you a very rough idea of what is the project "NovAnI" about.

transporters    energy    inhibitors    protein    peculiar    gram    medicinal    staphylococcus    difficult    pathogens    biochemical    coupling    given    give    antimalarial    un    potentially    chemistry    goals    importers    interdisciplinary    antibacterial    builds    sliding    mrsa    hit    anti    pharmacologists    cell    small    der    provides    agents    cutting    vitamin    repair    biosynthetic    incidence    first    aureus    absent    selectivity    circumventing    action    crystallographers    me    platform    combination    return    few    causative    antituberculotic    resistant    drugs    mode    dna    humans    scaffolds    dxs    infective    context    threat    strategies    identification    resistance    biochemists    emergence    rapid    agent    crossing    explored    negative    infections    mycobacterium    diseases    infectives    million    drug    molecule    erc    organic    fact    excellent    exhaustion    dnan    bacteria    collaborations    positive    tuberculosis    employing    synthetic    thereby    place    clamp    investment    methicillin    expertise    edge    flexibility    synergistic    position    unconventional    urgently    serious    health    wall    deaths    polymerase   

Project "NovAnI" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙367 €
 EC max contribution 1˙499˙367 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙367.00

Map

 Project objective

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed.

I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known:

1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development.

I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives.

This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVANI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVANI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

QUAMAP (2019)

Quasiconformal Methods in Analysis and Applications

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More